Nadunolimab clinical trials in AML/MDA and TNBC to be initiated in Q4 2024 and H2 2025, respectively September 3, 2024
FAILED TRIAL: Ph 3 PRESERVE 2 Trial of Trilaciclib Before 1L chemo in mTNBC did Not Achieve Statistical Significance in the Primary Endpoint of OS July 1, 2024
FAILED TRIAL: CAPItello-290 Ph 3 trial of Truqap (capivasertib) + chemo in locally advanced, inoperable or metastatic TNBC patients with PI3KCA/AKT1/PTEN alterations did not meet the dual primary endpoints of OS improvement June 25, 2024
Pivotal Ph 3 Trial of Trilaciclib to continue in metastatic TNBC Following Interim Analysis by IDMC February 26, 2024
Ph 3 PRESERVE 2 trial of Cosela in mTNBC to continue to final analysis following IDMC recommendation February 26, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial August 16, 2023
New Results from Ph 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an ADC May 18, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Encouraging early efficacy data from ModiFY Ph 1/2 trial announced: Modi-1 monotherapy showed PR and SD in SCCHN, ovarian, or TNBC patients February 22, 2023
Upcoming 2023 Readouts from Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib announced January 17, 2023
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
MARIO-3 Updates reported in Patients with 1L mTNBC Suggesting Potential Long-Term Patient Benefit of Eganelisib November 23, 2022
Initial Results From Ph 2 Trial Demonstrate Potential Of Trilaciclib To Reduce Adverse Events Related To An ADC November 16, 2022
Enrollment Completed in Global Multi-Center Ph 3 Clinical Trial of Trilaciclib in Patients with mTNBC October 19, 2022
KEYTRUDA® Receives Four New Approvals in Japan, Including in High-Risk Early-Stage TNBC October 5, 2022
FDA approved Lytgobi (futibatinib) for adults with advanced intrahepatic cholangiocarcinoma (iCCA) who have FGFR2 gene fusions or other rearrangements October 5, 2022
